Table 1 HBsAg and anti-HCV prevalence in PWID in the EU/EEA
Country | HBsAg | Anti-HCV | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Year | Sample size | Prevalence (95% CI) | Study design | Setting | Year | Sample size | Prevalence (95% CI) | Study design | Setting | |
Austria | – | – | – |  |  | 2013 | 48 | 31.3 (18.7–46.3) | DT | ODD |
Croatia | 2007 | 200 | 0.5 (0.0–2.8) | SP | PRI | 2007 | 200 | 44 (37.0–51.2) | SP | PRI |
Cyprus | 2013 | 82 | 6.1 (2.0–13.7) | DT | DTC | 2013 | 82 | 47.6 (36.4–58.9) | DT | DTC |
Czech Republic | – | – | – |  |  | 2013 | 1889 | 14.6 (13.1–16.3) | DT | NSP |
Denmark | – | – | – |  |  | 2008 | 223 | 52.5 (45.7–59.2) | SP (UAT) | ODD |
Finland | – | – | – |  |  | 2009 | 682 | 60.5 (56.8–64.3) | SP (UAT) | NSP |
Greece | 2013 | 1337 | 3.0 (2.2–4.1) | DT | DTC; LTS; OTH; PHL; PRI; STR; | 2013 | 1309 | 68.1 (65.5–70.6) | DT | DTC; LTS; PHL; PRI; OTH STR; |
Hungary | 2011 | 664 | 0.5 (0.1–1.3) | SP | DTC, NSP | 2011 | 652 | 24.1 (20.8–27.6) | SP | DTC; NSP |
Ireland | 2010 | 200 | 0.5 (0.0–2.8) | SP | PRI | 2010 | 200 | 41.5 (34.6–48.7) | SP | PRI |
Italy | – | – | – |  |  | 2010 | 743 | 60.5 (56.8–64.0) | DT | DTC |
Latvia | 2013 | 562 | 2.1 (1.1–3.7) | DT | DTC | 2013 | 522 | 70.1 (66.0–74.0) | DT | NSP |
Malta | – | – | – |  |  | 2013 | 109 | 13.8 (7.9–21.7) | DT | ANT; DTC; HTC; OHC; PHL; STI |
Norway | – |  | – |  |  | 2013 | 6342 | 63.0 (61.8–64.2) | SP | DTC |
Portugal | 2013 | 399 | 6.3 (4.1–9.1) | DT | DTC | 2013 | 414 | 84.3 (80.4–87.7) | DT | DTC |
Slovenia | – | – | – |  |  | 2009 | 112 | 32.1 (23.6–41.6) | DT | DTC |
United Kingdom | – | – | – |  |  | 2013 | 3144 | 49.1 (47.4–50.9) | SP (UAT) | DTC; LTS; OTH; NSP |